Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Molecular NeuroImaging
The overall goal of this imaging trial is to evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand. * To characterize \[18F\]MNI-952, a PET radioligand for imaging tau. * To visually and quantitatively assess brain uptake and pharmacokinetics of \[18F\]MNI-952, a PET imaging marker for tau pathology in individuals with Progressive Supranuclear Palsy (PSP) or Alzheimer's disease (AD) and compare with healthy volunteers (HV). * To evaluate the safety of a single injection of \[18F\]MNI-952. * To compare the distribution of tau (using \[18F\]MNI-952) and Aâ (using florbetapir) in AD subjects.
Age
18–90
Sex
ALL
Healthy volunteers
Accepted